Ionis Shares Updates in Phase 1/2 and Phase 3 Clinical Trials

Ionis Pharmaceuticals has shared a letter to the Angelman syndrome community on the ION582 clinical development program. The letter covers progress on the Phase 1/2 HALOS and Phase 3 REVEAL trials, as well as the recently announced CHAMPION trial to explore ION582 in additional genotypes.